Time to get proper diagnosis in multiple sclerosis and start disease-modifying therapy: the Highlands MS incidence study

被引：0
|
作者：
Artal, F. J. Carod [1 ]
机构：
[1] Raigmore Hosp, NHS Highlands, Neurol Dept, Inverness, Scotland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1354
引用
收藏
页码：769 / 770
页数：2
相关论文
共 50 条
  • [31] Multiple Sclerosis Disease-Modifying Therapy Prescribing Patterns in Ontario
    Marriott, James J.
    Mamdani, Muhammad
    Saposnik, Gustavo
    Gomes, Tara
    Manno, Michael
    O'Connor, Paul W.
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2013, 40 (01) : 67 - 72
  • [32] Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment
    Jakimovski, Dejan
    Awan, Samreen
    Eckert, Svetlana P.
    Farooq, Osman
    Weinstock-Guttman, Bianca
    CNS DRUGS, 2022, 36 (01) : 45 - 59
  • [33] Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment
    Dejan Jakimovski
    Samreen Awan
    Svetlana P. Eckert
    Osman Farooq
    Bianca Weinstock-Guttman
    CNS Drugs, 2022, 36 : 45 - 59
  • [34] Multiple sclerosis: Real-world long-term benefits of disease-modifying MS therapy
    Fyfe I.
    Nature Reviews Neurology, 2016, 12 (7) : 372 - 372
  • [35] Disease-modifying therapy improved depression symptoms in multiple sclerosis patients: the POSIDONIA study
    Montanari, E.
    Conti, M.
    Maimone, D.
    Clerici, V. Torri
    Plewnia, K.
    Frigo, M.
    Francia, A.
    Pala, A.
    Veneziano, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 321 - 321
  • [36] The use of disease-modifying agents in multiple sclerosis - by the Canadian Network of MS clinics
    O'Connor, Paul
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2008, 35 (02) : 127 - 129
  • [37] Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
    Molazadeh, Negar
    Sahraian, Mohammad Ali
    Ghajarzadeh, Mahsa
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2023, 14 (01) : 89 - 93
  • [38] Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS)
    Stamatellos, Vasileios-Periklis
    Papazisis, Georgios
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2023, 18 (01) : 39 - 50
  • [39] An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis
    Vaughn, Caila
    Bushra, Aisha
    Kolb, Channa
    Weinstock-Guttman, Bianca
    CNS DRUGS, 2018, 32 (02) : 161 - 178
  • [40] Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents
    Amato, MP
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (10) : 2115 - 2126
12345